Search PubMed⌕ Search

Biomedical subjects

M Rossi

Publications and source records attributed to M Rossi.

At least 685 records · Page 38Linked to original sources

[Acute leukemia. Case material and therapeutic results].

In the five years period 1969-1973, 22 cases of acute lymphoblastic (ALL) and 75 of acute myeloid leukaemia (AML) were observed in adults. In ALL, complete remission was obtained in 61% of cases. The median duration of remission worked out to be 3 months in the group of patients who died and more than 6 months in the patients still alive. The mean survival time was 7,8 and more than 10,6 months respectively. The various regimens of treatment used in the phase of induction appeared to be equally effective, whilst cyclic chemotherapy was found to be preferable in maintaining remission. As far as AML is concerned, complete remission was achieved in 25% of the patients with stem cells leukaemia, 50% in myeloblastic leukaemia and 33% in mielyomoocytic leulaemia. The median duration of remission was 3,5 and 9 months respectively. No case of promyelocytic leukaemia and erythroleukaemia achieved complete remission. The mean survival time was 3,4 months in stem cells leukaemia, 6 months in myeloblastic leukaemia, 6,6 months in myelomonocytic leukaemia, 0,4 months in promyelocytic leukaemia and 2,5 months in erythroleukaemia. In stem cells leukaemia, the highest frequency of remission was found in patients aged 13 to 20 years, whilst in myeloblastic and myelomonocytic leukaemia the most favourable results were obtained in patients aged 50 to 70 and 20 to 50 respectively. The longest mediam duration of remission and the best survival time was obtained in myelomonocytic leukaemia. The best rate of remission was achieved in the patients whose initial leukocyte count ranged from 10.000 to 50.000/mm-3. No patient with an initial WBC count above 50.000/mm-3 entered complete remission. The frequency of complete remission worked out to be much higher in the patients treated with cyclic chemotherapy according to the Hammersmith protocol, except in the case of stem cells leukaemia.

Adolescent↗

Enzymes of deoxythymidine triphosphate biosynthesis in Neurospora crassa mitochondria.

Intact mitochondria of Neurospora crassa incorporate deoxythymidine 5'-monophosphate (dTMP) into deoxyribonucleic acid but not the label from (methyl-3H) deoxythymidine. Mitochondrial homogenates contain deoxythymidylate kinase (EC 2.7.4.9), deoxycytidylate aminohydrolase (dCMP deaminase) (EC 3.5.4.12), and thymidylate synthetase (EC 2.1.1b), but not thymidine kinase (EC 2.7.1.21) activity. dTMP kinase is loosely bound to the mitochondrial membrane and is solubilized by 0.4 M KCl in mitochondrial homogenates, the dCMP aminohydrolase deaminase) is bound to the inner membrane and is not solubilized by 0.4 M KCl. dTMP synthetase activity is found in the 2,000 times g particulate fractions by homogenization of mitochondria in 0.4 M KCl. The dCMP deaminase activity found in the particulate fraction of the inner membrane is efficiently regulated by the products of the pathway: deoxycytidine 5'-triphosphate activates whereas deoxythymidine 5'-triphosphate inhibits, as found for the soluble enzyme from other sources. These data indicate that mitochondria of N. crassa contain specific enzymes for the biosynthesis of deoxythymidine triphosphate.

Adenosine Triphosphate↗